Form 4: Nurix Therapeutics Executive Gwenn Hansen Reports Stock Transactions

Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, reports the acquisition and disposal of common stock and restricted stock units to cover tax obligations.

Summary

• Gwenn Hansen, Chief Scientific Officer of Nurix Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On October 30, 2024, Hansen acquired shares of common stock through the vesting of restricted stock units (RSUs).
• Hansen also disposed of 3,437 shares of common stock at a weighted average price of $24.305 to cover tax withholding obligations related to the vesting of RSUs.
• The reported transactions resulted in Hansen beneficially owning 50,670 shares of common stock following the reported transactions.
• The transactions included the vesting of 3,207 RSUs, 2,000 RSUs and 3,750 RSUs.
• Following the transactions, Hansen beneficially owns 16,034, 12,000 and 37,500 restricted stock units respectively.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance.

Industry Context

Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. These filings are closely watched by investors as they can provide insights into management's view of the company's prospects.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares to cover tax obligations.

Key Dates